Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Increases By 57.1%

Posted by Brian Himes on Jun 17th, 2026

Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 828,958 shares, an increase of 57.1% from the May 14th total of 527,786 shares. Based on an average daily trading volume, of 263,322 shares, the days-to-cover ratio is currently 3.1 days. Approximately 15.7% of the shares of the stock are short sold.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock traded up $0.16 on Wednesday, hitting $2.86. The stock had a trading volume of 237,648 shares, compared to its average volume of 181,853. The stock has a 50 day moving average of $2.48 and a 200 day moving average of $3.34. Moleculin Biotech has a twelve month low of $1.79 and a twelve month high of $24.00. The firm has a market capitalization of $15.26 million, a P/E ratio of -0.16 and a beta of 1.77.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($3.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.33) by ($1.21). Equities analysts expect that Moleculin Biotech will post -5.1 earnings per share for the current year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on MBRX shares. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $22.00.

Get Our Latest Report on MBRX

About Moleculin Biotech

(Get Free Report)

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.